Evidence map›Paper›PMID 38731089›Full record

ArticleJournal of clinical medicine2024

Evaluation of a Combinatorial Immunotherapy Regimen That Can Cure Mice Bearing MYCN-Driven High-Risk Neuroblastoma That Resists Current Clinical Therapy.

Lauren Zebertavage, Allison Schopf, Megan Nielsen, Joel Matthews, Amy K Erbe, Taylor J Aiken, Sydney Katz, Claire Sun, Cole M Witt, Alexander L Rakhmilevich and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lauren ZebertavageDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.
Allison SchopfDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.
Megan NielsenDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.
Joel MatthewsDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.ORCID 0009-0009-1313-4327
Amy K ErbeDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.
Taylor J AikenDepartment of Surgery, University of Wisconsin, Madison, WI 53705, USA.
Sydney KatzDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.
Claire SunDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.
Cole M WittDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.
Alexander L RakhmilevichDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.
Paul M SondelDepartment of Human Oncology, University of Wisconsin, Madison, WI 53705, USA.

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
University of Wisconsin Institute for Clinical and Translational ResearchUL1TR002373 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI ELIZABETH S BURNSIDE, Allan R. Brasier · 2017 to 2026
$75.9M
Understanding and Overcoming Resistance to Immunotherapies in Childhood CancersU54CA232568 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI MACKALL, CRYSTAL, MARIS, JOHN M · 2018 to 2022
$13.1M
Radionuclide Production and Radiochemistry Core Description CoreP01CA250972 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI KIM, KYUNGMANN · 2020 to 2024
$12.5M
Enhancing Antibody-directed Innate Immunity to Improve Cancer OutcomeR35CA197078 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SONDEL, PAUL M · 2015 to 2021
$6.4M
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality ImmunotherapiesU01CA233102 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT, WEICHERT, JAMEY P · 2018 to 2022
$4.0M
NCATS NIH HHS UL1 TR002373NCI NIH HHS P01 CA250972NCI NIH HHS P30 CA014520NCI NIH HHS R35 CA197078NCI NIH HHS U01 CA233102NCI NIH HHS U54 CA232568NCI NIH HHS U54-CA232568NIH HHS R35-CA197078
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

anti-CD40anti-CTLA-4CpGGD2immunocytokineimmunotherapyMYCNneuroblastomarefractoryrelapse

Identifiers

PMID38731089
PMCPMC11084214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.